You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
Recruiting
  • Safety and Efficacy
  • anti-CD19 and anti-BCMA CAR
  • Immunomodulatory drugs
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
2021-05-17
May 17, 2021
S
Recruiting
  • Myeloma
  • +2 more
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
2020-12-15
Dec 15, 2020
O
Terminated
  • Multiple Myeloma
  • Encinitas, California
  • +5 more
2022-03-15
Mar 15, 2022
N
Completed
  • Multiple Myeloma
  • Allogeneic HSCT
  • +5 more
  • Birmingham, Alabama
  • +14 more
2022-01-25
Jan 25, 2022
O
Recruiting
  • High-risk Smoldering Multiple Myeloma
  • Multiple Myeloma
  • Boston, Massachusetts
  • +1 more
2021-10-18
Oct 18, 2021
M
Active, not recruiting
  • Multiple Myeloma
  • High Risk Smoldering Multiple Myeloma
  • Basking Ridge, New Jersey
  • +5 more
2021-11-15
Nov 15, 2021
I
Terminated
  • High Risk Smoldering Multiple Myeloma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
2020-11-18
Nov 18, 2020
D
Suspended
  • Smoldering Multiple Myeloma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-01-04
Jan 4, 2022
C
Active, not recruiting
  • Autologous Hematopoietic Stem Cell Transplant Recipient
  • +4 more
  • Duarte, California
    City of Hope
2022-03-17
Mar 17, 2022
M
Recruiting
  • Smoldering Plasma Cell Myeloma
  • Isatuximab
  • Laboratory Biomarker Analysis
  • New York, New York
  • +2 more
2021-11-30
Nov 30, 2021
S
Recruiting
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
2021-12-07
Dec 7, 2021
M
Active, not recruiting
  • Smoldering Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-23
Mar 23, 2022
U
Active, not recruiting
  • Multiple Myeloma
  • Birmingham, United Kingdom
  • +20 more
2021-09-10
Sep 10, 2021
P
Active, not recruiting
  • Smoldering Multiple Myeloma
  • Barcelona, Spain
  • +15 more
2021-02-15
Feb 15, 2021
I
Active, not recruiting
  • Smoldering Multiple Myeloma
  • Tampa, Florida
  • +9 more
2022-02-07
Feb 7, 2022
L
Unknown status
  • Smoldering Multiple Myeloma
  • PD-L1 peptide
  • Herlev, Denmark
    Department of Hematology, Universityhospital Herlev and Gentofte
2020-02-20
Feb 20, 2020
S
Completed
  • Multiple Myeloma
  • aMIL
  • No aMIL
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020-06-11
Jun 11, 2020
H
Active, not recruiting
  • Multiple Myeloma
  • Lymphoma
  • Washington, District of Columbia
  • +1 more
2021-12-02
Dec 2, 2021
A
Active, not recruiting
  • Multiple Myeloma
  • Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
  • Placebo 1.7 ml Subcutaneous Solution
  • Graz, Austria
  • +9 more
2021-02-08
Feb 8, 2021
N
Completed
  • Smoldering Multiple Myeloma
  • Fayetteville, Arkansas
  • +12 more
2020-12-11
Dec 11, 2020
N
Withdrawn
  • Multiple Myeloma
  • (no location specified)
2019-12-13
Dec 13, 2019
M
Recruiting
  • Acute Leukemia
  • +27 more
  • HSCT with TBI Regimen
  • HSCT with Non-TBI Regimen
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
2021-05-21
May 21, 2021
M
Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +13 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-08
Feb 8, 2022
U
Recruiting
  • Plasma Cell Leukemia
  • +2 more
  • Biospecimen Collection
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-10-18
Oct 18, 2021